Choosing a Molecular Testing Panel for Solid Tumors

Peter Voorhees, MD, discusses the integration of CAR T-cell therapy in early-relapsed myeloma and the importance of early T-cell–redirecting therapy use.

Peter WT Pisters, MD, MHCM, will retire as president of The University of Texas MD Anderson Cancer Center.

The FDA has granted fast track designation to varsetatug masetecan for relapsed/refractory metastatic colorectal cancer.

SYS6090, a first-in-class PD-1/IL-15 bispecific fusion protein, earned fast track status for MSS/pMMR metastatic colorectal cancer that has progressed on standard systemic therapy.

Cathy Eng, MD, FACP, FASCO, discusses how oncology fellows can navigate the journal submission and review process.

ASCO issued an alert regarding dwindling supplies of ifosfamide, which is used across testicular cancer and sarcoma regimens.

The WVU Heart and Vascular Institute and WVU Cancer Institute performed West Virginia’s first single-port robotic-assisted thoracoscopic lobectomy.

The FDA approval of daraxonrasib was based on data from the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.